Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 10/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 10/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10247080 | 1.00 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL10247153 | 0.81 | LMNA (0.50) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL10249658 | 0.77 | LMNA (0.47) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL10246865 | 0.75 | LMNA (0.54) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL10246936 | 0.75 | TAOK3 (0.52) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL10249684 | 0.73 | HTT (0.62) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL10247155 | 0.73 | LMNA (0.77) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL10247161 | 0.72 | CA12 (0.55) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL10246997 | 0.72 | LMNA (0.62) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL10246949 | 0.71 | KMT2A (0.58) | TAS1R3TAS1R1TAS1R2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012322-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | TAS1R3 3594/4885TAS1R1 3179/4885TAS1R2 2810/4885 |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | TAS1R3 3997/4885TAS1R1 3610/4885TAS1R2 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.